Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Biomaterials. 2011 Nov 26;33(5):1607–1617. doi: 10.1016/j.biomaterials.2011.11.011

Figure 6.

Figure 6

Immunohistochemistry a) IL-17 and b) IL-23 for i) normal skin, ii) inflammed skin induced by topical application of IMQ suspension, and inflammed skin after 5 days treatmnt of iii) spantide II and ketoprofen comprising gel (SP+KP gel) iv) ketoprofen comprising skin penetrating nanogels (KP-SPN) v) spantide II comprising skin penetrating nanogels (SP-SPN) vi) spantide II and ketoprofen comprising skin penetrating nanogels (SP+KP-SPN) and vii) a positive control, Topgraf® (tacrolimus ointment 0.1%). The presence of brown staining was considered a positive identification for activated IL-17 and IL-23.